Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Showing results for

THEO-260 is an oncolytic immunotherapy designed to effectively target cancer cells and cancer-associated fibroblasts while inducing immune activation in stroma-rich tumours. The US trial (OCTOPOD-IP) is exploring the safety and tolerability of intraperitoneal delivery of THEO-260 in high-grade serous or endometroid ovarian cancer.

The BioEscalator welcomes mitochondrial transplantation company, Recondria Therapeutics, as new tenant

Founded by Abhishek Srivastava and Jay Siddharth, Recondria Therapeutics is developing mitochondrial transplantation technology to help damaged or ageing cells recover their energy-producing function.

Biotix joins the BioEscalator community to advance AI-driven drug discovery for skin disease

Biotix, an AI-enabled biotech focused on the skin microbiome, has relocated from Haverhill Research Park, Cambridge, to the BioEscalator to expand its drug discovery work in inflammatory and immune-mediated skin conditions.

Theolytics’ ongoing US phase 1 OCTOPOD-IP trial of THEO-260 in ovarian cancer to be presented as a trial in progress at ASCO 2026

THEO-260 is an oncolytic immunotherapy designed to effectively target cancer cells and cancer-associated fibroblasts while inducing immune activation in stroma-rich tumours. The US trial (OCTOPOD-IP) is exploring the safety and tolerability of intraperitoneal delivery of THEO-260 in high-grade serous or endometroid ovarian cancer.

Infinitopes appoints Immuno-Oncology Pioneer Jo Brewer as Chief Scientific Officer (CSO) to advance therapeutic pipeline From clinical to commercialisation

Infinitopes, a biotechnology company developing novel and precision immunotherapy, announces the appointment of Jo Brewer, PhD, as Chief Scientific Officer and interim Chief Operating Officer.

Entelo Bio selected as one of 20 global teams to pioneer AI target discovery in ALS

Entelo Bio has been named one of 20 global winners of the Longitude Prize on ALS, receiving funding and access to one of the world’s largest ALS datasets to support AI-driven drug target discovery. In this interview, the Oxford spinout shares how the award will accelerate its platform development, collaborative research, and expansion into neuromuscular disease.

Theolytics announces first patient dosed in the OCTOPOD-IP Trial, a US phase 1 trial with THEO-260, a novel oncolytic immunotherapy targeting ovarian cancer

Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating intraperitoneal (IP) administration of THEO-260 for the treatment of women with Platinum-Resistant Ovarian Cancer (PROC) (NCT07211659).

The life of a BioEscalator apprentice, featuring geology, mental health and award nominations

Our apprentices, Billy Pullen & Becson Ody, bring ideas, initiative and new ways of doing things to the BioEscalator. This month, we've seen more examples of their drive and understanding of the workplace.

Entelo Bio raises $4M to transform human physical resilience

Entelo Bio, an AIxBio company focused on the biology of movement and ageing, emerges from stealth today with a total of $4 million in funding, led by Ananda Impact Ventures, with participation from The Creator Fund and US and European bio- and tech-focused angels.

Enara Bio presents first-in-class DARKFOX-Targeting bispecific T Cell engager ENA101 in oral presentation at AACR 2026, showcasing breakthrough potential in solid tumour immunotherapy

ENA101 targets DARKFOX®, a novel, cancer‑specific Dark Antigen encoded by a previously undiscovered alternative open reading frame (alt‑ORF) within FOXM1. DARKFOX was discovered and validated using Enara’s proprietary EDAPT® platform and represents a new class of highly tumour-specific targets derived from the dark proteome.

Alethio Therapeutics unveils ATX‑011, a breakthrough, mutation‑agnostic antibody for treating essential thrombocythemia – a c.$2B market, and strengthens leadership to accelerate path to IND

Alethio Therapeutics, a biopharmaceutical company developing novel treatments for myeloproliferative neoplasms (MPN), today announced the unveiling of ATX‑011, a first‑in‑class, mutation‑agnostic antibody with potential to disrupt the $2B Essential Thrombocythemia (ET) market. Alongside this, the Company announces the appointment of Steve R. Coats, PhD, a veteran biologics leader, as Chief Development Officer, to advance the ATX-011 programme towards IND submission, targeted for Q1 2027.

Bioarchitech secures strategic material license with the UK Health Security Agency (UKHSA) to support manufacturing and clinical development of BA-V151

Bioarchitech, Oxford, UK, an immuno-oncology therapeutics start-up company announces that it has secured a material license from the European Collection of Authenticated Cell Cultures (ECACC), UKHSA for a mammalian cell line to be developed as a scalable and high yield viral manufacturing platform and for the vector backbone of BA-V151, a preclinical stage candidate being developed as a treatment for metastatic cancers.

PepGen announces topline results from lowest dose (5 mg/kg) MAD cohort in the ongoing phase 2 FREEDOM2 study demonstrating favourable safety, splicing and vHOT data

PGN-EDODM1 was generally well-tolerated, with all adverse events being mild or moderate, and no serious adverse events reported. The mean splicing correction observed with PGN-EDODM1 (n=6) was 7.3%, compared to 6.8% for the placebo (n=2). Excluding one outlier patient, the treatment group showed a mean splicing correction of 22.9% (n=5). Promising trends were seen in vHOT in the PGN-EDODM1 treated group. The company is on track to report clinical data from the 10 mg/kg multiple dose cohort in the second half of 2026, with sufficient cash expected to fund operations into the second half of 2027.

BioEscalator joins Equinox partnership to drive inclusive growth

The BioEscalator is proud to be a founding signatory of Equinox (Equitable Innovation Oxford), a new initiative connecting research, business and communities to accelerate innovation and deliver inclusive growth in Oxford and the wider region.

Cardiovascular clinical scientist & diagnostic entrepreneur Professor Paul Leeson joins the BioEscalator Management Board

We are delighted to welcome Professor Paul Leeson to our Management Board - an expert in cardiovascular imaging and preventive cardiology, entrepreneur and supporter of translational research and spin-out creation.

Enara Bio to unveil first-in-class DARKFOX-targeting bispecific T cell engager ENA101 in oral presentation at AACR 2026, showcasing breakthrough potential for solid tumour immunotherapy

Enara Bio, a pioneer in Dark Antigen® discovery and bispecific T cell engager innovation, today announced new data to be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, highlighting its lead clinical candidate, ENA101, a first-in-class bispecific T cell engager (TCE) targeting DARKFOX®, a novel cancer-specific Dark Antigen discovered with Enara’s EDAPT® platform.

BioEscalator Bulletin - Spring 2026

Stay informed with the latest BioEscalator updates, tenant and alumni news in the Spring 2026 edition of the BioEscalator Bulletin.

OSE announces new board appointments

Professor Dame Molly Stevens joins as a Non-Executive Director and University representative. Professor Richard Hobbs also joins as a Non-Executive Director. Simon Boddie, the Chief Financial Officer of the University of Oxford, steps down.

International Women’s Day 2026: Celebrating Success Across the Bioscience Ecosystem

Q: What kind of biosciences event features being an actress, being a cool kid, twin babies, presenting to empty lecture theatres, offices with no toilets for women, and mentorship schemes that don’t work? A: The BioEscalator’s celebration of International Women’s Day 2026.

Let’s just get married – the story of an acquisition

"We decided to skip the engagement and just get married" – that’s how Hutano Diagnostics’ CEO Atherton Mutombwera describes his company’s acquisition by EDx Medical in 2023. The meeting of minds between him and the purchaser’s CEO, Dr Mike Hudson, was the culmination of six years of hard work by Atherton developing multiplex lateral flow diagnostics based on aptamers.

Theolytics awarded €8 million in Horizon Europe 2025 grant funding to advance phase 2 study of THEO-260 in ovarian cancer

Pending final negotiations, the grant will fund up to 20 patients in the OCTOPOD-IV Phase 2a expansion study of THEO-260 in platinum-resistant ovarian cancer. The competitive funding award highlights Theolytics’ innovative science and strong clinical development plan. The application is coordinated with several major international clinical centres and world-class partners.

Load More

Similar stories